The drug will launch within a week, it said, with no news yet on pricing, although Biogen did tell Reuters it would be in line with other recently launched ALS treatments and out-of-pocket costs ...

Medicare Advantage plans must cover Biogen’s (NASDAQ:BIIB) drug Qalsody for the treatment of ALS, according to a report. The U.S. Centers for Medicare & Medicaid Services has directed insurance ...

Biogen (BIIB) stock in focus as company and partner Eisai (ESALF) face delay in the EU launch of Alzheimer's drug lecanemab.

European Union regulators will review new information relating to the safety of Eisai Co.’s and Biogen Inc.’s medicine for ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $214.78, a high estimate of ...

the company's challenges in establishing its presence in the market for Alzheimer's drugs. "Biogen remains in transition, as management forges ahead with the buildout of its Alzheimer's disease ...

Biogen and Sage also stopped work on another experimental drug, SAGE-324 for the chronic treatment of essential tremor, after disappointing Phase 2 data. Another challenge for Sage came in the ...

FDA-approved ALS treatments available in the U.S. include Mitsubishi Tanabe's Radicava, generic drug riluzole, and Biogen's (BIIB.O), opens new tab Qalsody. Sign up here. Reporting by Puyaan Singh ...

Private Medicare plans must cover Biogen's ALS drug, US agency says Healthcare & Pharmaceuticalscategory· December 13, 2024 Corcept Therapeutics said on Wednesday its experimental drug failed to ...

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for Alzheimer’s disease in 2025. Companies including Biogen Inc. and Eli ...

(Bloomberg) -- Approvals for drugs from Biogen Inc. and Sarepta Therapeutics Inc. show flaws in the process US drug regulators use to speed approval for drugs to fill unmet needs, federal ...